Donald A. Bergstrom, serving as President and Chief Scientific Officer at Relay Therapeutics, Inc. (NASDAQ:RLAY), executed a sale of 8,660 shares of the company's common stock on July 6, 2026. The transaction resulted in proceeds totaling $162,028. According to filings, the shares were disposed of at prices ranging between $18.45 and $19.36 per share, yielding a weighted average sale price of $18.71.
The sale was conducted pursuant to a Rule 10b5-1 trading plan that Mr. Bergstrom adopted on October 30, 2025. This pre-arranged framework allows for the systematic sale of company stock regardless of market conditions, a standard mechanism for executive liquidity management that does not necessarily reflect internal sentiment regarding the company's near-term trajectory.
Following the execution of this transaction, Mr. Bergstrom's direct holding in Relay Therapeutics common stock stands at 409,897 shares. This position includes 15,037 shares underlying restricted stock units. The sale takes place as Relay Therapeutics shares trade near their 52-week high of $20.20. The stock has experienced a 450% gain over the past year and a 147% surge in the last six months, reflecting substantial investor interest in the company's clinical pipeline.
Recent corporate developments and analyst coverage have contributed to the current market environment for Relay Therapeutics. The company recently priced a public offering of 22,916,667 shares at $12 each, aiming to raise approximately $275 million before expenses. This capital raise is intended to bolster the company's financial resources to support ongoing clinical and operational activities.
In the analyst community, JPMorgan initiated coverage of Relay Therapeutics with an overweight rating and set a price target of $28. The firm cited the potential of zovegalisib, a PI3K inhibitor, as a key driver for this positive outlook. H.C. Wainwright also raised its price target to $28, following promising results from the Phase 2 ReInspire trial presented at an international conference.
Other institutional updates include Guggenheim increasing its price target to $26. Guggenheim noted that zovegalisib shows promise over existing treatments but highlighted concerns about low-grade hyperglycemia as a potential risk factor. Citizens raised its price target to $21, supported by strong trial data showing significant response rates for zovegalisib in treating vascular anomalies.
These developments indicate a period of strategic financial activity and positive clinical progress for Relay Therapeutics. The confluence of capital raising, analyst upgrades, and clinical data presentation suggests a critical juncture for the company as it navigates the commercialization and development of its lead asset.